Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of PIK dividend or equity fee recorded

The following table summarizes, by subsidiary, the PIK dividends, annual equity fees, and equity fees recorded by the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the partner companies’/subsidiaries’ certificates of incorporation for the years ended December 31, 2025 and 2024 ($ in thousands):


	PIK Dividend	Year Ended December 31,
Partner company	Date	2025		2024
Avenue	January 1		130		410
Cellvation	October 31		7		10
Checkpoint¹	January 1		53		8,633
Cyprium	January 1		299		291
Helocyte	January 1		40		39
Mustang	January 1		667		940
Oncogenuity	May 8		9		9
Urica	November 25		87		514
Fortress			(1,292)		(10,846)
Total		$	—	$	—

Note 1:

Instead of a PIK dividend, Checkpoint paid the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization. Due to the deconsolidation of Checkpoint in May 2025 related to the Sun Pharma transaction (see Note 3), Checkpoint no longer has this obligation to the Company.

Schedule of effective date and annual consulting fee payable by the subsidiary to the Company

The following table summarizes, by partner company/subsidiary, the effective date of the MSA and the annual consulting fee payable by the partner company/subsidiary to Fortress in quarterly installments ($ in thousands):



Partner Company/Subsidiary		Effective Date		2025		2024
Avenue¹		February 17, 2015		$	500		250
Cellvation		October 31, 2016			500		500
Checkpoint²		March 17, 2015			208		500
Cyprium		March 13, 2017			500		500
Helocyte		March 20, 2015			500		500
Mustang		March 13, 2015			500		500
Oncogenuity		February 10, 2017			500		500
Urica		November 7, 2017			500		500
Fortress					(3,708)		(3,750)
Consolidated (Income)/Expense				$	—	$	—

Note 1:

Avenue’s MSA fee for 2024 was subject to a Subscription and Forgiveness Agreement signed in November 2024.

Note 2:

Due to the deconsolidation of Checkpoint in May 2025 related to the Sun Pharma transaction (see Note 3), Checkpoint no longer has this obligation to the Company.